An analysis of data discovered a link between treatment with androgen deprivation therapy and new diagnoses of incident depression and anxiety in men with prostate cancer.
There was no significant benefit with long-term ADT, but researchers said there was a “clinically relevant” benefit in patients with high-risk disease.
Study confirms the care gap in bone health management and fracture prevention among older men with prostate cancer receiving androgen deprivation therapy.
In a phase 2 trial, 44% of men who received abiraterone with or without cabazitaxel prior to radical prostatectomy for high-risk prostate cancer achieved a pathologic complete response or minimal residual disease.
The meta-analysis, however, showed no clear oncologic benefit to prolonging neoadjuvant ADT before definitive radiation therapy for prostate cancer.
Enzalutamide was associated with net benefits in deterioration-free survival at 3 years, despite having some negative effects on health-related quality of life.
Study findings suggest a longer ADT duration than NCCN guidelines for patients with high-risk prostate cancer treated with EBRT alone.
Investigators found that men receiving androgen deprivation therapy for prostate cancer had a 1% rate of major adverse cardiovascular events.
Concomitant anti-androgen therapy may ameliorate the worse outcomes associated with delayed salvage radiation therapy for recurrent prostate cancer after radical surgery.
The median rPFS was 24.0 months in the apalutamide arm and 16.6 months in the placebo arm.
